The US health regulator has given its final approval to the drug firm Zydus Cadila for marketing Nateglinide tablets that are used in the treatment of diabetes in the American Market.
Cadila Healthcare has said in a BSE filing that Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Nateglinide tablets USP in the strength of 60 mg and 120 mg.
This Nateglinide tablet is an anti-diabetic agent which is used in managing type -2 diabetes mellitus and will be produced at the group’s formulation manufacturing facility at Pharma SEZ in Ahmedabad.
